Tamoxifen is the first-line treatment for estrogen receptor (ER)-positive breast cancer, but drug resistance appears in 30% of ER-positive BRCA patients and accounts for nearly all distant metastases. This evidence concerns the gene ESR1 and breast carcinoma.